<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg"/></p>
<p>此次收购包括亚太地区 14 种慢性疾病产品的 MAH 权利、商标和商业权利。来源：MiniStocker / Shutterstock.com。</p>
<p>珠峰医药全资子公司 EverSea Medicines（新加坡）已签署股份购买协议，条件性收购 Hasten Biopharmaceuticals，后者是 Hasten Biopharmaceuticals（亚洲）的子公司。</p>
<p>此次收购旨在增强珠峰医药在关键区域市场的存在感和商业能力。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>免疫肿瘤学（IO）- 主题智能</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>根据协议，珠峰医药将分三期支付总计 2.5 亿美元的对价：在交易完成时支付 1.5 亿美元，2028 年和 2029 年第一季度各支付 5000 万美元，具体取决于约定的先决条件。</p>
<p>Hasten Biopharmaceuticals（亚洲）还将在交易完成后十天内向珠峰医药支付 2 亿人民币（2920 万美元）的可退还押金。</p>
<p>交易完成后，珠峰医药将合并 Hasten Biopharmaceuticals 的财务结果。</p>
<p>此次收购包括商标和广泛的商业权利，以及 Hasten Biopharmaceuticals 在多个亚太地区拥有的 14 种品牌慢性疾病产品的 MAH 权利。</p>
<p>在 2025 年 12 月，Hasten Biopharmaceuticals 的正常化收入为 8223 万美元，EBITDA 为 2727 万美元。</p>
<p>该公司专注于慢性和急性/危重护理的处方药，目标是代谢和心血管领域。</p>
<p>珠峰医药的产品线专注于心血管、肾脏和代谢疾病等慢性疾病治疗领域。</p>
<p>其产品包括 Nefecon、Velsipity 和 Xerava，正在亚洲市场推进新药申请和报销流程。</p>
<p>该公司预计此次收购将进一步加快区域产品的商业化和海外收入的生成。</p>
<p>这还将扩展珠峰医药现有的商业化能力，从中国扩展到亚太地区，支持市场进入和国际增长所需基础设施的发展。</p>
<p>在 2026 年 2 月，珠峰医药与 Micot 签署了独家许可协议，以在中国和亚太地区（不包括日本）商业化 MT1013。</p>

国泰中证生物医药ETF

易方达恒生港股通创新药ETF

平安中证医疗创新ETF

<p>EverSea Medicines，作为 Everest Medicines 的子公司，已签署股份购买协议，以 2.5 亿美元收购 Hasten Biopharmaceuticals。该交易包括在亚太地区 14 种慢性疾病产品的 MAH 权利、商标和商业权利。此次收购旨在增强 Everest Medicines 的市场存在感和商业能力。Hasten Biopharmaceuticals 在 2025 年 12 月报告的正常化收入为 8223 万美元，EBITDA 为 2727 万美元。此次收购预计将加速产品商业化并支持国际增长</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg"/></p>
<p>The acquisition includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in Asia Pacific. Credit: MiniStocker / Shutterstock.com.</p>
<div class="lb-trans"><p>此次收购包括亚太地区 14 种慢性疾病产品的 MAH 权利、商标和商业权利。来源：MiniStocker / Shutterstock.com。</p>
</div><p>Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).</p>
<div class="lb-trans"><p>珠峰医药全资子公司 EverSea Medicines（新加坡）已签署股份购买协议，条件性收购 Hasten Biopharmaceuticals，后者是 Hasten Biopharmaceuticals（亚洲）的子公司。</p>
</div><p>The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets.</p>
<div class="lb-trans"><p>此次收购旨在增强珠峰医药在关键区域市场的存在感和商业能力。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Immuno-oncology (IO) - Thematic Intelligence</h4>
<div class="lb-trans"><h4>免疫肿瘤学（IO）- 主题智能</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Under the deal, Everest Medicines will pay a total consideration of $250m in three instalments: $150m at closing, and two further $50m payments due in the first quarters of 2028 and 2029, subject to agreed conditions precedent.</p>
<div class="lb-trans"><p>根据协议，珠峰医药将分三期支付总计 2.5 亿美元的对价：在交易完成时支付 1.5 亿美元，2028 年和 2029 年第一季度各支付 5000 万美元，具体取决于约定的先决条件。</p>
</div><p>Hasten Biopharmaceuticals (Asia) will also pay a refundable deposit of 200m yuan ($29.2m) to Everest Medicines within ten days after closing.</p>
<div class="lb-trans"><p>Hasten Biopharmaceuticals（亚洲）还将在交易完成后十天内向珠峰医药支付 2 亿人民币（2920 万美元）的可退还押金。</p>
</div><p>Upon closing, Everest Medicines will consolidate the financial results of Hasten Biopharmaceuticals.</p>
<div class="lb-trans"><p>交易完成后，珠峰医药将合并 Hasten Biopharmaceuticals 的财务结果。</p>
</div><p>The acquisition includes trademark and broad commercial rights and marketing authorisation holder (MAH) rights for 14 branded chronic disease products that are owned by Hasten Biopharmaceuticals in various Asia Pacific jurisdictions.</p>
<div class="lb-trans"><p>此次收购包括商标和广泛的商业权利，以及 Hasten Biopharmaceuticals 在多个亚太地区拥有的 14 种品牌慢性疾病产品的 MAH 权利。</p>
</div><p>In December 2025, Hasten Biopharmaceuticals posted normalised revenue of $82.23m and EBITDA of $27.27m.</p>
<div class="lb-trans"><p>在 2025 年 12 月，Hasten Biopharmaceuticals 的正常化收入为 8223 万美元，EBITDA 为 2727 万美元。</p>
</div><p>The company commercialises prescription pharmaceuticals with a focus on chronic and acute/critical care, targeting the metabolic and cardiovascular segments.</p>
<div class="lb-trans"><p>该公司专注于慢性和急性/危重护理的处方药，目标是代谢和心血管领域。</p>
</div><p>Everest Medicines has a pipeline that is focused on chronic disease therapeutic areas such as cardiovascular, kidney, and metabolic illnesses.</p>
<div class="lb-trans"><p>珠峰医药的产品线专注于心血管、肾脏和代谢疾病等慢性疾病治疗领域。</p>
</div><p>Its products, including Nefecon, Velsipity, and Xerava, are advancing through new drug application and reimbursement processes in Asian markets.</p>
<div class="lb-trans"><p>其产品包括 Nefecon、Velsipity 和 Xerava，正在亚洲市场推进新药申请和报销流程。</p>
</div><p>The company expects the acquisition to further expedite regional product commercialisation and overseas revenue generation.</p>
<div class="lb-trans"><p>该公司预计此次收购将进一步加快区域产品的商业化和海外收入的生成。</p>
</div><p>It will also expand Everest Medicines’ existing commercialisation capabilities from China to the Asia Pacific, supporting market entry and the development of infrastructure needed for international growth.</p>
<div class="lb-trans"><p>这还将扩展珠峰医药现有的商业化能力，从中国扩展到亚太地区，支持市场进入和国际增长所需基础设施的发展。</p>
</div><p>In February 2026, Everest Medicines signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding Japan).</p>
<div class="lb-trans"><p>在 2026 年 2 月，珠峰医药与 Micot 签署了独家许可协议，以在中国和亚太地区（不包括日本）商业化 MT1013。</p>
</div>

EverSea Medicines 将收购 Hasten Biopharmaceuticals